Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 19 Stomach Neoplasms 12 Colorectal Neoplasms 10 Rectal Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Esophageal Squamous Cell Carcinoma 5 Pancreatic Neoplasms 4 Esophageal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Neoplasm Metastasis 3 Nasopharyngeal Carcinoma 3 Lung Neoplasms 3 Triple Negative Breast Neoplasms 2 Endometrial Neoplasms 2 Turcot syndrome 1 Thyroid Neoplasms 1 Squamous Cell Non-small Cell Lung Cancer 1 Spinocerebellar Degenerations 1 Sarcoma 1 Salivary Gland Malignant Neoplasms 1 Resectable NSCLC 1 Recurrence 1 Rare Tumor 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms 1 NSCLC 1 Microsatellite Stable Metastatic Colorectal Cancer 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × sintilimab × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡